Condition (MeSH)
Coronary Thrombosis
ClinicalTrials.gov lists 23 trials for Coronary Thrombosis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
23 of the 23 trials are tagged with Coronary Thrombosis itself; the rest are tagged with a narrower condition beneath it.
When did Coronary Thrombosis trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 4 |
| 2010 | 2 |
| 2009 | 2 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 23 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Coronary Thrombosis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Not applicable | 3 |
| Observational | 11 |
How many Coronary Thrombosis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 13 |
| Suspended | 1 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Coronary Thrombosis trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AO GENERIUM | 1 |
| Cogentus Pharmaceuticals | 1 |
| Eisai Co., Ltd. | 1 |
| Hillel Yaffe Medical Center | 1 |
Which drugs are being tested for Coronary Thrombosis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Magnesium Pantoprazole | 1 |
| veliflapon (DG-031) | 1 |
| Tenecteplase | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Reduced duration (6 months) DAPT | 1 |
| during one week for the active treatments | 1 |
| GNR-060 | 1 |
| Plavix (clopidogrel 75 mg) and aspirin | 1 |
| CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Coronary Thrombosis trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| In hospital mortality | 110 | 1 |
| Unstable Angina or Angina Requiring Hospitalization | 21 | 1 |
| Major Bleeding | 9 | 1 |
| Non-fatal Myocardial Infarction | 9 | 1 |
| Stroke or Transitory Cerebral Ischemic Event | 9 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Coronary Thrombosis? (509)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. | Journal of the American College of Cardiology | 2026 | Yes |
| Diabetic Status and Thrombogenicity: Association and Prognostic Implications After Percutaneous Coronary Intervention. | JACC. Cardiovascular interventions | 2025 | Yes |
| PARIS coronary thrombosis risk score combined with D-dimer to guide new oral anticoagulant antithrombotic therapy in patients with acute coronary syndrome after percutaneous coronary intervention: study protocol for the PRIDE-ACS trial. | BMJ open | 2025 | Yes |
| Interventional thrombus modification in STEMI. | Nature reviews. Cardiology | 2024 | Yes |
| Failed Thrombus Aspiration and Reduced Myocardial Perfusion in Patients With STEMI and Large Thrombus Burden. | JACC. Cardiovascular interventions | 2024 | Yes |
Showing 5 of 509 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.